论文部分内容阅读
用改良的Troost微量生化分析法对31例正常人,50例原发性肝癌(PHC),23例肝炎后肝硬化,20例急性肝炎,20例慢性肝炎病人血清α-L-岩藻糖苷酶活性(AFU)进行了测定。结果表明,PHC组的AFU活性(0.6474±0.2205mmol·s~(-1)/L)显著高于正常对照组和其他疾病组(P<0.001)。以AFU≥0.4200mmol·s~(-1)/L为判断值,对PHC的诊断敏感性及特异性分别达90%和95%,对AFP阴性的PHC的诊断阳性率为92%,与AFP联合检测,PHC诊断阳性率达96%。提示AFU检测对原发性肝癌具有重要的诊断价值。
A modified Troost microbiochemical assay was used to analyze serum α-L-fucosidase in 31 normal subjects, 50 primary liver cancer (PHC), 23 posthepatitic cirrhosis, 20 acute hepatitis, and 20 chronic hepatitis patients. Activity (AFU) was measured. The results showed that the AFU activity in PHC group (0.6474±0.2205 mmol·s-1/L) was significantly higher than that in the normal control group and other disease groups (P<0.001). The diagnostic sensitivity and specificity of PHC were 90% and 95%, respectively, with AFU ≥ 0.4200 mmol·s -1 / L. The positive rate of AFP-negative PHC was 92%. Combined detection, PHC diagnostic positive rate of 96%. AFU detection has important diagnostic value for primary liver cancer.